Pharmafile Logo
Pharmafocus logo
Advanced Search

Clovis Oncology discontinue phase 2 bladder cancer trial

April 15, 2019
Sales and Marketing Cancer, Clovis Oncology, US, bladder cancer, metastatic bladder cancer

Colorado-based pharma firm Clovis Oncology has said in a filing to the US Securities and Exchange Commission that it is …

News

Bayer VP elected to two of the firm’s executive committees

April 12, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, appointment

Dr Monika Lessl has been appointed to Bayer Foundations’ executive committee, selected by the German pharmaceutical firm’s Board of Management …

Appointment
manabe

Daiichi Sankyo name current COO Sunao Manabe as firm’s new CEO

April 12, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Daiichi Sankyo have said Sunao Manabe, the company’s current COO will take over from George Nakayama as the firm’s new …

Appointment
28246711066_52e38bc591_z

NHS Confederation chief says news of Brexit extension is a relief

April 12, 2019
EU, NHS, UK, brexit, health, medicine

Niall Dickson, the Chief Executive of the NHS Confederation, has said news of the decision to extend the Brexit deadline …

News
darren_cline

GW Pharma announce Darren Cline as company’s new Chief Commercial Officer

April 12, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

GW Pharmaceuticals have announced the appointment of Darren Cline as the company’s new US Chief Commercial Officer. Cline will lead …

Appointment
merckwindow_web

FDA expands Keytruda label to include stage 3 and 4 non-small cell lung cancer

April 12, 2019
Medical Communications, Research and Development Cancer, MSD, keytruda, lung cancer, non-small cell lung cancer, pharma

MSD has revealed that its anti-PD-1 therapy Keytruda (pembrolizumab) has received expanded indication from the FDA to include the first-line …

News
janssen_latest_logo_on_sign_closer

Janssen’s Symtuza around 90% effective in achieving undetectable HIV-1 viral loads, when used immediately following diagnosis

April 12, 2019
Medical Communications HIV, Janssen, Symtuza, pharma

Janssen has lifted the curtain on data from the first Phase 3 trial investigating the efficacy of Symtuza (darunavir 800mg, …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

April 12, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, BMS, Eisai, Gilead, MSD, Pfizer, ViiV, indivior

This week was an excellent week for recommendations and approvals after Eisai, MSD, Pfizer, BMS and ViiV scored wins. Meanwhile …

News
bacteria-3662695_960_720

Throat lozenges could be contributing to antimicrobial resistance

April 12, 2019
Medical Communications AMR, Antibiotics, OTC, WHO, antimicrobial, health

Over the counter (OTC) throat lozenges could be contributing to antimicrobial resistance (AMR) according to research presented at this year’s …

News
opioid_pills

Opioid crisis cost US government nearly $38 billion in lost taxes

April 11, 2019
Medical Communications, Research and Development US, government, opioid crisis, opioids, public health, tax revenue

The opioid epidemic may have cost US state and federal governments as much as $37.8 billion in lost tax revenue, …

News
trafficjamdelhi

Traffic pollution linked to four million childhood asthma cases each year

April 11, 2019
Research and Development Air pollution, NO2, Traffic, asthma, emissions, pollution, public health

Air pollution is linked to four million cases of childhood asthma each year, according to research published in The Lancet …

News
hannah_pender

Living with a rare chromosome disorder

April 11, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Inv Dup Del 8p, feature, patient experience, pharma

Rebecca Pender’s daughter Hannah lives with the ultra-rare condition Inv Dup Del 8p, a genetic arrangement that affects just 80 …

Feature
1468995876_rb-centre-for-scientific-excellence

Reckitt Benckiser to unveil £105 R&D site in Hull by end of June

April 11, 2019
Manufacturing and Production Hull, R&D, Reckitt Benckiser, UK, pharma

Reckitt Benckiser (RB) has announced that its £105 million research and development facility in the UK city of Hull – …

News

Researchers use CRISPR to reveal gene targets in 30 types of cancer

April 11, 2019
Research and Development Cancer, crispr, drug development, genes, genetics, oncology

Researchers at the Wellcome Sanger Institute and Open Targets have been able to identify thousands of genes which play a …

News
novartis_window

Novartis’ Kisqali combo rejected by NICE for advanced breast cancer

April 11, 2019
Sales and Marketing Kisqali, NHS, NICE, Novartis, pharma

Novartis’ Kisqali (ribociclib) has been rejected for use on the NHS by NICE for the treatment of advanced breast cancer, …

News
gilead-sciences

Gilead to lay off one fifth of sales force

April 11, 2019
Sales and Marketing Gilead, Jobs, Letairis, Ranexa, redundancy, sales

Gilead Sciences is preparing to lay off around a fifth of its salesforce in anticipation for the expiry of patents …

News
fdaoutsideweb

FDA green lights Amgen and UCB’s Evenity in postmenopausal osteoporosis patients

April 10, 2019
Research and Development, Sales and Marketing Amgen, Evenity, FDA, UCB Pharma, osteoporosis, pharma

The FDA has decided to approve Amgen and UCB Pharma’s Evenity (romosozumab-aqqg) for the treatment of postmenopausal osteoporosis patients at …

News
suboxone_sl_tabs

Indivior shares fall by 70% after allegations of fraud

April 10, 2019
Research and Development Virginia, indivior, opioid crisis, opioids, suboxone

Shares in London-listed Indivior plummeted this morning after US Federal prosecutors said the British drugmaker had deceived doctors as to …

News
lynparza

Europe approves Lynparza in HER2-, gBRCAm advanced breast cancer

April 10, 2019
Research and Development, Sales and Marketing AstraZeneca, Cancer, MSD, breast cancer, lynparza, pharma

Lynparza (olparib), the poly ADP ribose polymerase (PARP) inhibitor developed by AstraZeneca and MSD, has been awarded marketing approval by …

News
brooklyn-bridge-768668_960_720

New Yorkers must be vaccinated or face a fine

April 10, 2019
Research and Development Brooklyn, New York, infectious diseases, measles, public health, vaccines

A public health emergency has been declared in New York following an outbreak of measles. Residents of certain postcodes in …

News
The Gateway to Local Adoption Series

Latest content

Could targeting the molecular causes of infertility finally transform IVF success rates?

January 29, 2026

Digital mental health technologies – a valuable tool in supporting people with depression and anxiety

January 29, 2026

Barts Health NHS Trust collaborates with H.I.G. Realty on healthcare innovation building

January 29, 2026

Rentschler Biopharma appoints Detra Glinatsis as Head of Business Development US

January 29, 2026

Five Facts about spinal muscular atrophy

January 28, 2026